Exclusion of pregnant and lactating women from COVID-19 vaccine trials: a missed opportunity

Harriette Gillian Christine Van Spall^{1

2

3

4}

Affiliations

¹ Department of Medicine, McMaster University, Hamilton, ON, Canada.
² Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
³ Population Health Research Institute, 20 Copeland Avenue, David Braley Research Building, Suite C3-117, Hamilton, ON L8L 0A3, Canada.
⁴ ICES, McMaster University, Canada.

Harriette Gillian Christine Van Spall. Eur Heart J. 2021.

. 2021 Jul 21;42(28):2724-2726.

doi: 10.1093/eurheartj/ehab103.

Harriette Gillian Christine Van Spall^{1

2

3

4}

¹ Department of Medicine, McMaster University, Hamilton, ON, Canada.
² Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
³ Population Health Research Institute, 20 Copeland Avenue, David Braley Research Building, Suite C3-117, Hamilton, ON L8L 0A3, Canada.
⁴ ICES, McMaster University, Canada.

No abstract available

Figures

1. Doshi P, Will Covid-19 vaccines save lives? Current trials aren’t designed to tell us. BMJ 2020;371; m4037. doi: 10.1136/bmj.m4037. - PubMed
1. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007;297:1233–1240. - PubMed
1. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KA, Morabito KM, O’Dell S, Schmidt SD, Swanson PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2-preliminary report. N Engl J Med 2020;383:1920–1931. - PMC - PubMed
1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. Safety and efficacy of the BNT162b2 mRNA Covid-19. N Engl J Med 2020;383:2603–2615. - PMC - PubMed
1. Oliver S. Clinical Considerations for Populations Included in Phase 1a. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/COVI... (21 January 2021).